Advertisement

What is the role of HPV typing in the United States now and in the next five years in a vaccinated population?

      Abstract

      Objective

      To review the current state of HPV typing of the vaccinated population in the United States and potential for typing of this population over the next 5 years.

      Methods

      An expert forum conducted on September 12–13, 2008, by the Society of Gynecologic Oncologists including 56 experts in cervical cancer and titled “Future strategies of cervical cancer prevention: what do we need to do now to prepare?”

      Results

      In principle, screening with HPV DNA testing for oncogenic genotypes followed by cytologic triage has attractive features that may serve well the screening needs of a post-vaccination era in the US. Particularly in light of the recent FDA approval of a HPV genotyping test, the group focused on how typing could be used to assist clinical decisions and whether its implementation would be cost-effective. Furthermore, it was agreed upon that HPV typing should not be used to determine who should be vaccinated against HPV. There was considerable discussion regarding the potential misuse and overuse of HPV typing in low risk women among healthcare providers.

      Conclusions

      As HPV typing technologies gain traction in the United States, its appropriate use will depend on the evolving natural history of the vaccinated cohort, continued educational efforts of healthcare providers, and most importantly, creating an integrated approach to cervical cancer prevention that will lead to a greater decrease in the incidence of cervical disease in the US while allowing for cost equipoise.
      On September 12–13, 2008, the Society of Gynecologic Oncologists (SGO) convened a symposium of 56 cervical cancer experts titled “Future strategies of cervical cancer prevention: what do we need to do now to prepare?” to discuss evidence-based strategies in cervical cancer prevention and control, including HPV vaccination. This paper is the second in a series of manuscripts which highlight concepts, information, obstacles and approaches discussed during the Forum's sessions and focuses on the current state of HPV typing of the vaccinated population in the United States and typing of this population over the next 5 years.

      Keywords

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bosch F.X.
        • de Sanjose S.
        Chapter 1: human papillomavirus and cervical cancer—burden and assessment of causality.
        J Natl Cancer Inst Monogr. 2003; 31: 3-13
        • Kjaer S.
        • Hogdall E.
        • Frederiksen K.
        • et al.
        The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period.
        Cancer Res. Nov 1 2006; 66: 10630-10636
        • Koshiol J.
        • Lindsay L.
        • Pimenta J.M.
        • Poole C.
        • Jenkins D.
        • Smith J.S.
        Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis.
        Am J Epidemiol. Jul 15 2008; 168: 123-137
        • Wright Jr., T.C.
        • Massad L.S.
        • Dunton C.J.
        • Spitzer M.
        • Wilkinson E.J.
        • Solomon D.
        2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests.
        Am J Obstet Gynecol. Oct 2007; 197: 346-355
        • Kulasingam S.L.
        • Kim J.J.
        • Lawrence W.F.
        • et al.
        Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS).
        J Natl Cancer Inst. Jan 18 2006; 98: 92-100
        • Kim J.J.
        • Wright T.C.
        • Goldie S.J.
        Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance.
        Jama. May 8 2002; 287: 2382-2390
        • Kim J.J.
        • Wright T.C.
        • Goldie S.J.
        Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy.
        J Natl Cancer Inst. Jun 15 2005; 97: 888-895
        • Smith J.S.
        • Lindsay L.
        • Hoots B.
        • et al.
        Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update.
        Int J Cancer. Aug 1 2007; 121: 621-632
        • Herzog T.J.
        • Monk B.J.
        Reducing the burden of glandular carcinomas of the uterine cervix.
        Am J Obstet Gynecol. Dec 2007; 197: 566-571
        • Huh W.K.
        • The Quadrivalent HPV Vaccine Phase IIb/III Investigators
        Impact of quadrivalent human papillomavirus (HPV) types 6/11/16/18 virus-like particle vaccine on the incidence of abnormal Pap test and cervical procedures.
        Gynecol Oncol. March 2008; 108 (Abstract #20): S10
        • Clifford G.M.
        • Rana R.K.
        • Franceschi S.
        • Smith J.S.
        • Gough G.
        • Pimenta J.M.
        Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer.
        Cancer Epidemiol Biomarkers Prev. May 2005; 14: 1157-1164
        • Dillner J.
        • Rebolj M.
        • Birembaut P.
        • Petry K.U.
        • Szarewski A.
        • Munk C.
        • et al.
        Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study.
        BMJ. Oct 13 2008; 337: a1754
        • Franco E.L.
        • Bosch F.X.
        • Cuzick J.
        • Schiller J.T.
        • Garnett G.P.
        • Meheus A.
        • et al.
        Chapter 29: knowledge gaps and priorities for research on prevention of HPV infection and cervical cancer.
        Vaccine. Aug 31 2006; 24: S3/242-9
        • Franco E.L.
        • Cuzick J.
        • Hildesheim A.
        • de Sanjose S.
        Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination.
        Vaccine. Aug 31 2006; 24 (S3/171-S3/177)
        • Kulasingam S.L.
        • Myers E.R.
        Potential health and economic impact of adding a human papillomavirus vaccine to screening programs.
        JAMA. 2003; 290: 781-789
        • Nanda K.
        • McCrory D.C.
        • Myers E.R.
        • Bastian L.A.
        • Hasselblad V.
        • Hickey J.D.
        • et al.
        Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review.
        Ann Intern Med. 2000 May 16; 132: 810-819
      1. Cervical Cancer Screening. ACOG Practice Bulletin. Number 109, December 2009.

        • Kiviat N.B.
        • Hawes S.E.
        • Feng Q.
        Screening for cervical cancer in the era of the HPV vaccine—the urgent need for both new screening guidelines and new biomarkers.
        J Natl Cancer Inst. 2008 Mar 5; 100: 290-291
        • Leinonen M.
        • Nieminen P.
        • Kotaniemi-Talonen L.
        • Malila N.
        • Tarkkanen J.
        • Laurila P.
        • et al.
        Age-specific evaluation of primary human papillomavirus screening vs. conventional cytology in a randomized setting.
        J Natl Cancer Inst. Dec 2 2009; 101: 1612-1623
        • Guo M.
        • Lin C.Y.
        • Gong Y.
        • et al.
        Human papillomavirus genotyping for the eight oncogenic types can improve specificity of HPV testing in women with mildly abnormal Pap results.
        Mod Pathol. Aug 2008; 21: 1037-1043
        • Thrall M.J.
        • Smith D.A.
        • Mody D.R.
        Women >/=30 years of age with low grade squamous intraepithelial lesion (LSIL) have low positivity rates when cotested for high-risk human papillomavirus: should we reconsider HPV triage for LSIL in older women?.
        Diagn Cytopathol. 2009 Nov 5; ([Electronic publication ahead of print])
        • Khan M.J.
        • Castle P.E.
        • Lorincz A.T.
        • Wacholder S.
        • Sherman M.
        • Scott D.R.
        • et al.
        The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.
        J Natl Cancer Inst. 2005 Jul 20; 97: 1072-1079
        • Castle P.E.
        • Solomon D.
        • Schiffman M.
        • Wheeler C.M.
        Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities.
        J Natl Cancer Inst. 2005 Jul 20; 97: 1066-1071
      2. ASCCP 2009 Algorithm: Use of HPV Genotyping to Manage HPV HR * Positive/Cytology Negative Women 30 Years and Older (http://www.asccp.org/pdfs/consensus/hpv_genotyping_20090320.pdf).

      3. Cervista Package Insert.